{"id":"74751b36-1ee4-5474-a032-67b64df6aceb","stable_key":"d8050016-13c9-5391-9d61-63de73590053:zeaxanthin-zvf-mpod-null","predicate":"does_not_significantly_differ_in","statement":"MPOD rose across the three active arms, with no significant between-group difference (P=0.47).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"c5a0219d-f0f6-52b4-8490-1683bf5fbc00","mechanism_event_label":"The study did not establish one arm as superior for pigment density.","subject":{"id":"e6275391-bf4b-5b05-806e-c91ba01e64f6","slug":"zvf-treatment-arms","display_name":"ZVF trial zeaxanthin, lutein and combined active arms","entity_type_key":"chemical_species"},"object":{"id":"6fae34f7-a295-5fdf-b161-199b28bb3685","slug":"human-macular-pigment-optical-density","display_name":"Human macular pigment optical density","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c5a0219d-f0f6-52b4-8490-1683bf5fbc00","stable_key":"d8050016-13c9-5391-9d61-63de73590053:zeaxanthin-zvf-mpod-null-event","event_type":"observed_intervention","label":"The study did not establish one arm as superior for pigment density.","description":"MPOD rose across the three active arms, with no significant between-group difference (P=0.47).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5dd84367-3f8e-5a3f-b952-a96174ea51fa","slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"},"role":"active_comparator_or_combination","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"e6275391-bf4b-5b05-806e-c91ba01e64f6","slug":"zvf-treatment-arms","display_name":"ZVF trial zeaxanthin, lutein and combined active arms","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6fae34f7-a295-5fdf-b161-199b28bb3685","slug":"human-macular-pigment-optical-density","display_name":"Human macular pigment optical density","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/zeaxanthin-research/22027699.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e\", \"start_char\": 0, \"end_char\": 3131, \"text_sha256\": \"849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Small randomized active-comparator ZVF trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"One year; 8 mg zeaxanthin, 8 mg zeaxanthin plus 9 mg lutein, or 9 mg lutein comparator","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The so-called faux placebo was active lutein. Small unequal arms, multiple outcomes and borderline tests limit claims of superiority; proposed competition was not directly tested.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Zeaxanthin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"zeaxanthin","display_name":"Dietary (3R,3-prime-R)-zeaxanthin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"60 patients with mild-to-moderate AMD; 57 men","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The study did not establish one arm as superior for pigment density.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[zeaxanthin-p22027699] Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. (2011). https://pubmed.ncbi.nlm.nih.gov/22027699/ DOI: 10.1016/j.optm.2011.08.008","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Macular pigment and visual tasks","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5e5b6a60-8056-536c-a731-8482befc6959","evidence_kind":"source_excerpt","locator":"Lines 977-988","start_line":977,"end_line":988,"excerpt":"### zeaxanthin-zvf-mpod-null\nMPOD rose across the three active arms, with no significant between-group difference (P=0.47).\nCondition category: normal\nnutrient_topic: Zeaxanthin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The study did not establish one arm as superior for pigment density.\norganism: 60 patients with mild-to-moderate AMD; 57 men\ntissue_or_cell_type: Macular pigment and visual tasks\nexperimental_model: Small randomized active-comparator ZVF trial\nlimitations: The so-called faux placebo was active lutein. Small unequal arms, multiple outcomes and borderline tests limit claims of superiority; proposed competition was not directly tested.\nexposure: One year; 8 mg zeaxanthin, 8 mg zeaxanthin plus 9 mg lutein, or 9 mg lutein comparator\nevidence_span: {\"source_cache\": \"artifacts/zeaxanthin-research/22027699.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e\", \"start_char\": 0, \"end_char\": 3131, \"text_sha256\": \"849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e\"}\n[zeaxanthin-p22027699] Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. (2011). https://pubmed.ncbi.nlm.nih.gov/22027699/ DOI: 10.1016/j.optm.2011.08.008","model_system":"Small randomized active-comparator ZVF trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [zeaxanthin-p22027699] Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. (2011). https://pubmed.ncbi.nlm.nih.gov/22027699/ DOI: 10.1016/j.optm.2011.08.008","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"df7effe5-d60c-525e-bd48-1518e1a03c51","stable_key":"import-d8050016-13c9-5391-9d61-63de73590053","title":"Zeaxanthin: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f872aef57169cee72edccda6652f3359e58cdf2e5427b507b83c32a9126ac7c1","revision_id":"dcd90b3a-8c34-57a8-999b-5ae1d2633943","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}